PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4325442

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
D. TRAVIS WILSON	10/10/2013

RECEIVING PARTY DATA

Name:	STEALTH PEPTIDES INTERNATIONAL, INC.	
Street Address:	2ND FLOOR, LE PRINCE DE GALLES	
Internal Address:	3-5 AVENUE DES CITRONNIERS	
City:	MONACO	
State/Country:	MONACO	
Postal Code:	98000	

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	61840760
Application Number:	14392293

CORRESPONDENCE DATA

Fax Number: (608)258-4258

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6082584285

Email: jadamo@foley.com
Correspondent Name: REBECCA HAYS

Address Line 1: FOLEY & LARDNER LLP
Address Line 2: 150 EAST GILMAN STREET
Address Line 4: MADISON, WISCONSIN 53703

ATTORNEY DOCKET NUMBER:	091151-0317
NAME OF SUBMITTER:	JENEEN ADAMO
SIGNATURE:	/JENEEN ADAMO/
DATE SIGNED:	03/19/2017

Total Attachments: 6

source=Family 25C Assignment for '760 Wilson#page1.tif source=Family 25C Assignment for '760 Wilson#page2.tif source=Family 25C Assignment for '760 Wilson#page3.tif

PATENT 504278760 REEL: 041628 FRAME: 0057

source=Family 25C Assignment for '760 Wilson#page4.tif source=Family 25C Assignment for '760 Wilson#page5.tif source=Family 25C Assignment for '760 Wilson#page6.tif

PATENT REEL: 041628 FRAME: 0058

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to as "ASSIGNOR") has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto

STEALTH PEPTIDES INTERNATIONAL, INC.

2nd Floor, Le Prince de Galles 3-5 Avenue des Citronniers MC 98000 Monaco

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to the inventions set forth in the attached *Schedule A*, as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the Patent Cooperation Treaty, the Paris Convention and any other international agreement; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors

Page 1 of 6

and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **Foley & Lardner LLP** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of Foley & Lardner LLP do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

(Remainder of page intentionally left blank)

_
eć
he ty,
ιy, he
1

SCHEDULE A

Application No.	Fitle	Filing Date	Atty. Dkt. No.
61/716,867	METHODS FOR REDUCING LEVELS OF C-REACTIVE PROTEIN, HEART FAILURE AND RISK FACTORS ASSOCIATED WITH HEART FAILURE	10/22/2012	091151-0264
61/823,305	METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING	5/14/2013	091151-0296
61/840,317	PEPTIDE THERAPEUTICS AND METHODS FOR USING SAME	06/27/2013	091151-0300
61/822,752	METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH	5/13/2013	091151-0301
61/840,922	THIODIGALACTOSIDES AND METHODS FOR USING SAME	06/28/2013	091151-0310
61/839,743	METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH	06/26/2013	091151-0311

Application No.	Title -	Filing Date	Atty. Dkt. No.
61/839,750	METHODS AND COMPOSITIONS FOR NORMALIZING THE LEVELS OF CARDIOLIPIN REMODELING GENES IN HEART FAILURE	06/26/2013	091151-0312
61/861,244	METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING LEBERS HEREDITARY OPTIC NEUROPATHY	08/01/2013	091151-0316
61/840,760	METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS	06/28/2013	091151-0317
61/861,712	METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF PORPHYRIA	08/02/2013	091151-0321
61/861,806	METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA	08/02/2013	091151-0322

Application No.	Title	Filing Date	Atty. Dkt. No.
61/864,876	AROMATIC-CATIONIC PEPTIDES, COMPOSITIONS AND METHODS FOR USING SAME	08/12/2013	091151-0327
61/871,661	METHODS FOR TREATMENT OF ISCHEMIC HEART DISEASE	08/29/2013	091151-0328

Page 6 of 6